An open-label, randomized clinical trial comparing Etacizin versus Propafenone in Atrial Fibrillation

Condition studied

Atrial fibrillation

Investigational medicinal product(s)

Eligibility

Primary endpoint

Recurrence of atrial fibrillation over 6 months of the treatment after restored sinus rhythm

Endpoint detail

Proportion of participants with pharmacological cardioversion during Phase I, The proportion of participants who meet clinical criteria for electrical cardioversion during Phase II, Time of recurrence of atrial fibrillation during Phase II, Change in Atrial fibrillation effect on quality of life from baseline to study end, Rate of hospitalizations related to atrial fibrillation during Phase II, A composite of cardiovascular death, myocardial infarction, acute coronary revascularization, and stroke (MACE), The heart rate variabilty in treatment groups